Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 960 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX KOMISE V XXXXXXXXX XXXXXXXXX (EU) 2020/1182

xx xxx 19. xxxxxx 2020,

kterým xx xxx účely xxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxxxx xxxx část 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx parlamentu x Rady (ES) x. 1272/2008 x xxxxxxxxxxx, označování x xxxxxx látek x xxxxx

(Xxxx x xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x xxxxxxx xx xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx x balení xxxxx x xxxxx, x xxxxx a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x xxxxx xxxxxxxx (XX) x. 1907/2006&xxxx;(1), x xxxxxxx na xx. 37 xxxx. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x xxxxx 3 přílohy XX xxxxxxxx (ES) č. 1272/2008 obsahuje xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxx xx xxxxxxx kritérií xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx I xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx xxxxx („xxxxxxxx“) xxxx x souladu x xxxxxxx 37 xxxxxxxx (XX) x. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxx látek x xxxxxxxxxxx nebo xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx některých jiných xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx xxxxx Xxxxx pro xxxxxxxxxx xxxxx („XXX“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx stran, xx xxxxxx xxxxxx, aktualizovat xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx látek. Xxxxxxx xxxxxxxxxx xxxxxx XXX xxxx:

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx dusičné... %[X ≤ 70 %],

—

xxxxxxxxxx ze dne 9. března 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx,xxxxx &xx; 5 μx x poměru xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, trimethoxy(vinyl)silanu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx xxx (N-hydroxy-N-nitrosocyklohexylaminato-O,O’)-mědi, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko ze xxx 14. xxxx 2018 ohledně dioktyltin-dilaurátu, [1] xxxxxxxx, dioktyl-, xxx(xxxx acyloxy) xxxxxxxx [2],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, tetraglymu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx paklobutrazolu (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. ledna 2019 xxxxxxx 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (ISO), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. března 2018 ohledně X-(+)-xxxxxx xxxxxxxx, (2S)-2-hydroxypropanové kyseliny,

—

stanovisko xx dne 9. xxxxxx 2018 ohledně 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx glyoxylové kyseliny …%,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfátu, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx dne 9. března 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanonu,

—

stanovisko xx xxx 14. xxxx 2018 ohledně xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [MBIT],

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [NMA],

—

stanovisko xx xxx 15. xxxxx 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), isopropyl [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx rostliny Xxxxxxxxxxx indica xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx uhličitým],

—

stanovisko ze xxx 8. xxxxxx 2018 ohledně xxxxxxxx xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [D4],

—

stanovisko ze xxx 30. listopadu 2018 xxxxxxx pirimifos-methylu (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx dichlordioktylstannanu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně olova,

—

stanovisko xx dne 14. xxxx 2018 ohledně 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (ISO), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx azoxystrobinu (XXX), xxxxxx (E)-2-{2-[6-(2-kyanofenoxy)pyrimidin-4-yloxy]fenyl}-3-methoxyakrylátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (ISO), (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxxxx (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [OIT],

—

stanovisko xx xxx 14. září 2018 ohledně hymexazolu (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. března 2018 xxxxxxx pymetrozinu (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx imiprothrinu (XXX), reakční směsi: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko ze xxx 14. xxxx 2018 butanon-oximu, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxx 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, hexyl 2-[4-(diethylamin)-2-hydroxybenzoyl]benzoátu.

(3)

Pokud xxx o xxxxx xxxxx (xxxxx XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) a 082–014–00–7 (xxxxxxxx olovo; [xxxxxx xxxxxx ≥ 1 xx];)), XXX xx xxxx xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 navrhl xxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx i xxxxxxxxx formu. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx rozpouštění xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, ke xxxxxxxxxx xxxxxxx xxxxxx xxxxxx x xxxxxxxx k xxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxx forem jiných xxxx x existujících xxxxxxxxx x xxxxxxx XX xxxx RAC xxxxxxx další xxxxxxxxx xxxx, zda má xxx xx xxxxxxxxx x xxxxxxxxx xxxxx xxxxx použita xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx xxxx xxxxxxxxxx xxxx xxxxxxx poznatky, x xxxxx vyplývá, xx environmentální xxxxxxxxxxx xxx xxxxxxxxx xxxxx, xxx ji doporučilo xxxxxxxxxx xxxxxx XXX, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx formu proto xxxxxx xxxxxxxx xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx RAC xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx CAS 111-76-2), pro xxxxx xxxxxxxxxxxxx „akutní xxxxxxxx (xxxxxxxxx)“ xxxx předloženy xxxx xxxxxxx xxxxxxxx, xx xxxxxxx xxxxxxx, xx klasifikace xxx xxxx třídu xxxxxxxxxxxxx xxxxxxxxxxxx ve xxxxxxxxxx xxxxxx RAC, jež xx xxxxxxx xx xxxxxxxx xxxxxxx, xxxxxx xxx xxxxxx. Xxxx xxxxx nebezpečnosti xx xxxxx neměla být x xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xxxxxxx, xxxxx XXX nebude xxx xxxxxxx xxxxxxxxx x xxxxx novým xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx třídy xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxx XXX, xx zařazeny být xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 by xxxxx xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx nových xxxx xxxxxxxxxxxxxxx harmonizovaných xxxxxxxxxxx xx nemělo xxx, x výhradou xxxxxxxxxxx regulatorních xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx potřebují xxxxxxx xxxx xx to, xxx přizpůsobili xxxxxxxxxx x xxxxxx látek x xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxxxx x prodali xxxxxxxxx xxxxxx. Xxxx doba xx rovněž xxxxxxxx x xxxx, aby xxxxxxxxxx xxxx dostatek xxxx přijmout xxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx dodržování dalších xxxxxxxx požadavků, xxxxx xxxxxxxx v důsledku xxxx xxxxxxxxxxx podle xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx x xx. 22 odst. 1 xxxx. f) xxxxxxxx Evropského parlamentu x Xxxx (XX) x. 1907/2006&xxxx;(3) xxxx xxxxxxxxx stanovené x xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by však xxxx xxx xxxxxxxx, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx. To xx x xxxxxxx x xxxxxxxxx xxxxx xx. 61 xxxx. 2 xxxxxxxx (XX) x. 1272/2008,

XXXXXXX TOTO XXXXXXXX:

Článek 1

Změny nařízení (XX) x. 1272/2008

Xxxxxxx 3 x xxxxx 3 xxxxxxx VI xxxxxxxx (ES) x. 1272/2008 xx mění x xxxxxxx x xxxxxxxx tohoto xxxxxxxx.

Xxxxxx 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx xxxx xx vyhlášení x Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx xx xxx xxx 1. xxxxxx 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx x směsi xxxxxxxxxxxxx, xxxxxxxxxx x baleny x xxxxxxx x xxxxxxxxx (XX) č. 1272/2008 ve znění xxxxxx xxxxxxxx xxxxx xxxxx xxxx 1. xxxxxx 2022.

Xxxx xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx státech.

V Bruselu xxx 19. května 2020.

Xx Xxxxxx

Xxxxxx VON XXX LEYEN

předsedkyně

(1)  manaÚř. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 xx xxx 18. prosince 2006

x xxxxxxxxxx, hodnocení, xxxxxxxxxx x omezování xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx xxxxxxxx 1999/45/XX x x xxxxxxx xxxxxxxx Xxxx (XXX) x. 793/93, nařízení Xxxxxx (XX) č. 1488/94, směrnice Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX a 2000/21/ES (Xx. věst. L 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 528/2012 xx xxx 22. května 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x xxxxxx xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 v xxxxx 3 xxxx xxxxx:

1)

Xxxxxxxx xx tyto xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx název

Číslo XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx faktory a XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx nebezpečnosti

Kódy standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Ox. Liq. 3

Xxxxx Xxx. 3

Skin Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 xx/x (páry)

Skin Xxxx. 1 X; X314: X ≥ 20 %

Xxxx Corr. 1X; H314: 5 % ≤ X &xx; 20 %

B“

„014-048-00-5

vlákna x karbidu křemíku (x průměru < 3 μm, xxxxx &xx; 5 μx x x poměrem xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Carc. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Liq. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

STOT XX 3

XXXX XX 1

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X225

X331

X301

X336

X370 (horní xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx cesty, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (páry)

orální: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: xx 0,9 mm a xx 6,0 xx; xxxxx částic: xx 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Acute Xxx. 4

XXXX XX 2

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (játra)

H318

H410

orální: ATE = 360 xx/xx XX

X = 1

M = 1“

„050-031-00-9

dioktylcín-dilaurát; [1]

stannan, xxxxxxx-, xxx(xxxx acyloxy) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

X360X

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

ipkonazol (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

STOT XX 2

Aquatic Xxxxxxx 1

X360X

X302

X373 (oči, kůže, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx TH

M = 100“

„603-238-00-9

bis(2-(2-methoxyethoxy)ethyl)-ether; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Xxxxx Xxx. 4

Acute Xxx. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-bis(brommethyl)propan-1,3-diol

221-967-7

3296-90-0

Carc. 1B

Muta. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Sens. 1

H317

GHS07

Wng

H317“

„605-041-00-3

2-(4-terc-butylbenzyl)propanal

201-289-8

80-54-6

Repr. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (ISO);

S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Xxx. 4

XXXX RE. 2

Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX RE 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: ATE = 500 mg/kg XX

X = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (ISO);

methyl-4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylát

–

317815-83-1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1000

M = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 S)-2-hydroxypropanová xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Liq. 3

Xxxx. 2

Xxxx. 1B

Acute Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Sens. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Xxx. 1

Skin Xxxx. 1B

H318

H317

GHS05

GHS07

Dgr

H318

H317

B“

„607-746-00-1

natrium-N-(hydroxymethyl)glycinát;

[formaldehyd xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX SE 3

Xxxx Irrit. 2

Xxx Xxxxx. 2

Skin Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 xx/x (prach xxxx mlha)

orální: XXX = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný;

cyklohexylhydroxydiazen-1-oxid, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Xxxxx Xxx. 3

XXXX XX 2

Xxxx Irrit. 2

Eye Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (játra)

H315

H318

H411

GHS02

GHS06

GHS08

GHS05

GHS09

Dgr

H228

H301

H373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Chronic 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1B

Acute Xxx. 2

Xxxxx Xxx. 3

XXXX XX 1

Eye Xxx. 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalační: ATE = 0,14 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

flurochloridon (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1B

Acute Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 mg/kg XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Tox. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Eye Dam. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; H315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; X319: 0,025 % ≤ X < 3 %

Xxxx Xxxx. 1 X; X317: C ≥ 0,0015 %

M = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1 A

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 mg/kg XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(difluormethyl)-1-methyl-N-(3‘,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid;

fluxapyroxad

–

907204-31-3

Lact.

Aquatic Xxxxx 1

Aquatic Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1B

Muta. 1X

XXXX XX 1

X350

X340

X372 (periferní xxxxxxx systém)

GHS08

Dgr

H350

H340

H372 (xxxxxxxxx xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-karboxanilid;

penflufen

–

494793-67-8

Carc. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX RE 2

Aquatic Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, výtažek [xxxx xxxxxxxx za xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx indica xxx skořápek, xxxxxxxxxxx xxxxxxxxxxxxxx oxidem xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

H412

H412“

2)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx nahrazují xxxxxx položkami:

Indexové číslo

Chemický xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx a kategorií xxxxxxxxxxxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy doplň. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Acute Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: C ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X < 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Chronic 1

X361x ***

H410

GHS08

GHS09

Wng

H361f ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

STOT RE 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (nervový xxxxxx)

X410

xxxxxx: XXX = 1 414 xx/xx XX

X = 1&xxxx;000

X = 1 000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1X

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxxxx 3

H360D

H330

H372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1X; X360 X: C ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (prach xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-ethyl-4,4-dioktyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradekanoát; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (imunitní xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx prášek; [xxxxxx xxxxxx < 1 mm]

231-100-4

7439-92-1

Repr. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Tox. 4*

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: ATE = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Sens. 1

Aquatic Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 xx/xx XX orální: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx nebo xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (ISO);

(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Acute Xxx. 3

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: ATE = 300 xx/xx XX xxxxxx: ATE = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

H361d

H373 (xxx, nervový xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, nervový xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Acute Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (xxxxx nebo xxxx)

xxxxxxxx: ATE = 311 mg/kg XX xxxxxx: ATE = 125 xx/xx TH

Skin Xxxx. 1 A; X317: C ≥ 0,0015 %

M = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Acute Xxx. 4

Xxx Xxx. 1

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: ATE = 1&xxxx;600 mg/kg XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

pymetrozin (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční směs: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Acute Xxx. 4

Acute Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (nervový xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (nervový xxxxxx; orální, inhalační)

H410

inhalační: XXX = 1,4 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 550 xx/xx XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; ethylmethylketoxim, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Tox. 4

Xxxxx Xxx. 3

XXXX XX 3

XXXX XX 1

XXXX XX 2

Skin Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX xxxxxx: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Irrit. 2

Aquatic Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.